Effectiveness of Intraoperative Mitomycin C in Maintaining the Patency of a Frontal Sinusotomy: A Preliminary Report of a Double-Blind Randomized Placebo-Controlled Trial

Abstract

One-time intraoperative topical MMC is not effective in reducing postoperative frontal recess stenosis in both primary and revision cases.

The effects of repetitious topical use of mitomycin C on antrostomy patency in maxillary antrostomy created rabbit model

“…In the study, aiming to study the effect of MMC on frontal recess, overall 45 patients, were included, of which 20 were revision cases; 0.5 mg/ml MMC was applied to frontal recess for 4 min and frontal recess areas were measured and calculated at 1, 3, and 6 months. It was finally reported that single dose inraoperative MMC did not produce any difference compared to control side in frontal recess narrowing [20]. Finally, in the study of Kim et al [11], measuring the narrowing of maxillary sinus ostium enlarged after ESS at first, third and sixth months, it was reported that topical MMC decreased ostium narrowing in a statistically significant manner only in first month and that no difference was established at third and sixth months.…”

“…In the study of Park et al [18], 0.4 and 1 mg/ml concentrations were compared, with no significant difference between them. In clinical studies, concentrations of 0.4 and 0.5 mg/ml were used [11,19,20]. In the present study, MMC was applied at the concentration of 0.6 mg/ml.…”

The frontal osteoplastic flap: does it still have a place in rhinological surgery?

“…16 Chan et al performed a prospective, double-blinded, randomised, placebocontrolled study in which patients received one intraoperative application of either mitomycin C (0.5 mg/ ml) or placebo, for 4 minutes. 17 They found no significant difference in frontal ostium patency. As the mitomycin C concentration and application time differed in these two studies, further research may be required to elucidate the effect, if any, of mitomycin C on frontal ostium patency.…”

Topical Heparin: A Promising Agent for the Prevention of Tracheal Stenosis in Airway Surgery

“…Decreased cell proliferation is seen in a dose-dependent manner within the first 5 min of exposure, though continuous exposure may lead to cell death. These effects of MMC have been shown in surgical treatments for pterygium [23,24], endoscopic sinus procedures [25], and dacryocystorhinostomy [26]. Therefore, MMC may be used to decrease scar formation in medicine.…”